STOCKHOLM – March 31, 2022 – Please find ContextVision’s Annual Report 2021 attached. The report can also be found on the company’s website: www.contextvision.se Printed copies of the report will be distributed upon request by e-mail: For inquiries, please contact CFO Markus Hökerberg E-mail: ### About ContextVision ContextVision is a medical technology software company […]
STOCKHOLM – March 31, 2022 – ContextVision hereby invites shareholders to the Annual General Meeting on May 4, 2022. Please find attached the invitation including agenda and details on how to register and vote. Please contact: for any questions regarding the AGM. For inquiries, please contact CFO Markus Hökerberg E-mail:
ContextVision AB (“ContextVision” or the “Company”) will, in accordance with the press release published on 2 February 2022, distribute all shares in its wholly-owned subsidiary INIFY Laboratories AB (“INIFY”) to the shareholders of ContextVision. The shares in INIFY are expected to be delivered to shareholders who have their shares registered at Euroclear Sweden AB around […]
Stockholm, February 2nd, at the extraordinary general meeting in ContextVision AB (“ContextVision” or the “Company”) held on 10 December 2021 the meeting resolved to distribute all shares in the wholly-owned company INIFY Laboratories AB, company registration number 559345-4431 (“INIFY”) to the shareholders of the Company. The board of directors has determined the record date for […]
ContextVision today announces that the Board of Directors of ContextVision has decided to make a strategic shift and focus its pathology business unit entirely on the establishment of an AI based pathology lab service.
INIFY Prostate® shown to accurately outline suspicious prostate cancer in study with two prominent medical centers
ContextVision today announced that results from a US clinical evaluation were presented at the Pathology Visions Congress in Las Vegas, USA.
In the Pan-European multicenter clinical study FirstPath, INIFY Prostate produced highly accurate, robust and homogenous results at all sites
STOCKHOLM – August 31, 2021 – ContextVision, a medical technology software company specializing in image processing, image analysis and decision support tools for digital pathology, today announced that results from FirstPath – a European multicenter clinical study evaluating performance of INIFY® Prostate in routine clinical practice – were presented at the European Congress of Pathology by […]
ContextVision announces agreement with two renowned US cancer centers for clinical evaluation of INIFY® Prostate
STOCKHOLM – July 6, 2021 – ContextVision, a medical technology software company specializing in image processing, image analysis and decision support tools for digital pathology, today announced that agreements to conduct a multicenter clinical study of ContextVision’s digital pathology product INIFY® Prostate have been signed with the Ohio State University Comprehensive Cancer Center – Arthur G. […]
On March 25, 16:00 CET (15:00 GMT), ContextVision and The Pathologist teamed up to host a free webinar: "Experience and results from using INIFY® Prostate Screening – in the fully digitalized pathology workflow at Cannizzaro Hospital, Italy". Here, Dr Filippo Fraggetta shared his experience of using INIFY Prostate Screening, as well as preliminary results from the hospital's ongoing clinical study. Now available on demand – register here for access.
ContextVision announces signed contract with Vall d’Hebron for clinical evaluation of INIFY® Prostate Screening
INIFY® Prostate Screening is a powerful AI-based software that predicts, outlines and quantifies suspicious cancerous areas in a series of prostate biopsies.